University of Oxford Confidence in Concept Scheme – Round 4

Lead Research Organisation: University of Oxford

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
publication icon
Ambrose S (2017) Native Desorption Electrospray Ionization Liberates Soluble and Membrane Protein Complexes from Surfaces. in Angewandte Chemie (International ed. in English)

publication icon
Frago S (2016) Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist. in Proceedings of the National Academy of Sciences of the United States of America

publication icon
Gill MR (2017) Targeted radionuclide therapy in combined-modality regimens. in The Lancet. Oncology

 
Description Appointed to the Scientific Advisory Board of Universal Cells
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Cell and Gene Therapy SAB Meeting
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Participation in Annual SAB Meeting of the Cell and Gene Therapy Catapult
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact Discussions informed future direction and practice of the CGT Catapult so as to optimise economic benefits to UK plc.
 
Description Cancer Research UK Oxford Centre Development Fund
Amount £15,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 02/2017
 
Description Cell based assays with Freestyle Microfluidics (DPhil Studentship) - Edmund Walsh Project
Amount £72,000 (GBP)
Organisation Iota Sciences Ltd. 
Sector Private
Country United Kingdom
Start  
 
Description Confidence in Concept
Amount £42,207 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 08/2018
 
Description Departmental PhD studentship for Rik van der Veen, Nuffield Dept. of Medicine, University of Oxford
Amount £95,430 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Departmental PhD studentship for Romain Guyon, Nuffield Dept. of Medicine, University of Oxford
Amount £95,430 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Development Fund Grant
Amount £14,600 (GBP)
Funding ID CRUKDF 0716-PF 
Organisation Cancer Research UK 
Department Cancer Research UK (CRUK) Oxford Centre
Sector Private
Country United Kingdom
Start 09/2016 
End 09/2017
 
Description EIT Health PhD/DPhil Doctoral Transition Fellowships
Amount € 42,000,000 (EUR)
Organisation European Institute of Innovation and Technology (EIT) 
Sector Public
Country Hungary
Start 01/2016 
End 12/2017
 
Description EIT Health Rare Cancer Project (KIC) Stage 1
Amount € 750,000 (EUR)
Organisation European Institute of Innovation and Technology (EIT) 
Sector Public
Country Hungary
Start 03/2016 
End 12/2018
 
Description Follow-on funding
Amount £100,000 (GBP)
Organisation Numares GmbH 
Sector Private
Country Germany
Start 03/2018 
End 02/2020
 
Description Functional location of airway inflammation in eosinophilic asthma
Amount £471,790 (GBP)
Funding ID EP/R042160/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2018 
End 12/2021
 
Description High sensitivity staging and monitoring for multiple sclerosis utilising metabolomics analysis of blood - Daniel Anthony Project
Amount £240,227 (GBP)
Organisation Multiple Sclerosis Society 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Lab282
Amount £231,405 (GBP)
Funding ID OUI 15169 
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 08/2018
 
Description Lord Leonard and Lady Estelle Wolfson Foundation Translation Award - Sunetra Gupta Project
Amount £50,000 (GBP)
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description MPLS Translation Award - Sunetra Gupta Project
Amount £71,729 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC CiC Award Oxford
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2017
 
Description MRC Confidence in Concept Round 4
Amount £33,835 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2016 
End 08/2018
 
Description Merck Grant for Multiple Sclerosis Innovation (GMSI) - Daniel Anthony Project
Amount € 366,339 (EUR)
Organisation Merck 
Sector Private
Country Germany
Start  
 
Description Project Grant
Amount £9,700 (GBP)
Funding ID OHSRC 1231 
Organisation Oxford Radcliffe Hospitals Charitable Fund 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Proof of Concept Award - Sunetra Gupta Project
Amount € 149,307 (EUR)
Organisation European Research Council (ERC) 
Sector Public
Country Belgium
Start  
 
Description RIO Clinical Trial: Set up award
Amount £90,267 (GBP)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 10/2018 
End 09/2019
 
Description Research project grant
Amount £37,000 (GBP)
Funding ID M638 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description Single administration of prime-boost malaria vaccine enabled by engineering advancements in precise vaccine encapsulation methods - Anita Milicic Project
Amount £48,000 (GBP)
Organisation Liverpool School of Tropical Medicine 
Sector Academic/University
Country United Kingdom
Start  
 
Description The PITCH Study Arm
Amount £199,999 (GBP)
Organisation amfAR, The Foundation for AIDS Research 
Sector Charity/Non Profit
Country United States
Start 10/2018 
End 09/2021
 
Description UCSF
Amount £66,497 (GBP)
Organisation Oxford Innovation Ltd 
Sector Private
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description Using Genome Variation to Sort Extremely Rare Cell Populations for Clinical Application
Amount £59,529 (GBP)
Organisation Medical and Life Sciences Translational Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 03/2020
 
Title Microfluidic sorting 
Description Assay developed to microfluidic droplets to enrich and sort very rare cell populations 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact Working with Physical Chemistry this method is being optimised for clinical application. Patents currently being applied for 
 
Title Refining sample handling and collection procedures - Sibson project 
Description By fostering new collaborations and having dedicated research assistant time in the clinic, we have been able to refine our sample handling and collection procedures with direct clinical feedback. This has included dedicated pro-formas and optimised handling and processing procedures which has resulted in higher recruitment rates and will be useful for undertaking further similar studies. 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? No  
Impact Optimised handling and processing procedures which has resulted in higher recruitment rates and will be useful for undertaking further similar studies. 
 
Title Sequencing bioinformatics 
Description Application of sureselect enrichment to rare DNA integrants in clinical samples 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact The SOP for this method will be made available following publication This technique allows next gen sequencing of rare proviral HIV sequences - currently not possible consistently using present methodology Manuscript in preparation 
 
Description Assay development to facilitate vaccine progression for Shingles 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution Transfer of assay and SOP to other laboratories. We will collaborate with Prof Helen Fletcher, based at the London School of Hygiene & Tropical Medicine, to transfer the newly developed assay and compare the outputs for reproducibility, accuracy and robustness.
Collaborator Contribution To facilitate the progress to market of new VZV-specific vaccines, we propose to develop a standardized peptide-based ELISPOT assay, which will be specific, reproducible, reliable and easily transferrable. Works carried out in Prof. Fletcher's laboratory will aid in the assessment of the ease to which the assay can be transferred.
Impact Collaboration in place; results pending.
Start Year 2017
 
Description Collaboration/Partner 
Organisation Vaccitech Ltd
Country United Kingdom 
Sector Private 
PI Contribution The commercial partner for this application are interested in further assessing the viability of the end product(s) that have been borne out of this research and other funded work in the same area.
Collaborator Contribution Ongoing work in the same field.
Impact Ongoing.
Start Year 2017
 
Description Department of Chemistry, University of Bristol 
Organisation University of Bristol
Department School of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Professor Matthew Crump on the structure and function of domain 11 of IGF2R. Sharing reagents and experiments.
Collaborator Contribution Development of FRET based assays for free IGF2 using covalent linkage of IGF2 and domain 11, validated with NMR.
Impact Multiple co-authored publications. Patent application co-IP.
Start Year 2006
 
Description Department of Chemistry, University of Sheffield 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Research collaboration to develop new chemical class of radiosensitizer for drug delivery. Synthetic source of chemical(s) for MRC CiC award.
Collaborator Contribution Partners bring chemical synthesis expertise.
Impact Multi-disciplinary (Chemistry) to add to Biological/Medical Science.
Start Year 2016
 
Description Dept Of Physical Chemistry, University of Oxford 
Organisation University of Oxford
Department Physical and Theoretical Chemistry Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution Research collaboration to develop microfluidic diagnostic platforms. Awarded MRC CiC grant and UCSF award.
Collaborator Contribution Partners bring expertise in microfluidics
Impact CIC Funding UCSF funding Patents pending
Start Year 2016
 
Description Diagnosis of brain tumours by biofluid metabolomics 
Organisation University of Oxford
Department Department of Oncology
Country United Kingdom 
Sector Academic/University 
PI Contribution We have established a collaboration with clinical colleagues in the Department of Oncology to obtain patient samples for metabolomics analysis. Our contribution is to undertake all sample processing and analysis, together with computational modelling and data interpretation.
Collaborator Contribution Our collaborators have facilitated sample collection from patients at their regular clinics.
Impact STEM for Britain Parliamentary Exhibition: Silver Medal Winner (post-doc on project). Wellcome Institutional Strategic Support Fund award (post-doc on project co-I): Developing new approaches to early disease detection using a primary care cohort with vague non-specific symptoms; £15k
Start Year 2016
 
Description Imaging of IGF2-TRAP 
Organisation University of Coimbra
Country Portugal 
Sector Academic/University 
PI Contribution Provided proteins for DOTA labelling
Collaborator Contribution Labelling and imaging of IGF2-TRAP using PET CT
Impact None yet
Start Year 2017
 
Description Imperial and King's College 
Organisation Imperial College London
Department Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration
Collaborator Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network
Impact Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed)
Start Year 2014
 
Description Imperial and King's College 
Organisation King's College London
Department Division of Immunology, Infection & Inflammatory Diseases (DIIID)
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration
Collaborator Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network
Impact Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed)
Start Year 2014
 
Description Monoclonal antibody production against vaccine antigen 
Organisation Envigo
Country United Kingdom 
Sector Private 
PI Contribution We have secured funding for this collaboration. We developed and supplied the protein vaccine antigen and will test functionality of mAb generated by different clones selected by our collaborator.
Collaborator Contribution Antibodies specific to our novel vaccine antigen do not exist leading to a reliance on non-specific fusion tags. In collaboration with us, our partner will supply this valuable new resource which will enable accurate data interpretation of the effects of new vaccine candidates.
Impact Collaboration in place; results pending.
Start Year 2017
 
Description Partnership with Numares AG - Daniel Anthony Project 
Organisation Numares GmbH
Country Germany 
Sector Private 
PI Contribution Provision of IP, ongoing development of research
Collaborator Contribution Take a license from existing IP, pay ongoing patent costs and fund an extension of the project to translate methods into a clinical setting
Impact None yet
Start Year 2016
 
Description RIO Clinical Trial 
Organisation Imperial College London
Department Faculty of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK.
Collaborator Contribution Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays
Impact Set-up grant from BMGF Knowledge exchange for assays
Start Year 2018
 
Description RIO Clinical Trial 
Organisation Rockefeller University
Department Laboratory of Virology and Infectious Disease
Country United States 
Sector Academic/University 
PI Contribution This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK.
Collaborator Contribution Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays
Impact Set-up grant from BMGF Knowledge exchange for assays
Start Year 2018
 
Description RIO Trial - Set Up award 
Organisation Rockefeller University
Country United States 
Sector Academic/University 
PI Contribution Sequence potential participants for the trial Develop the protocol
Collaborator Contribution Sponsorship Protocol development Knowledge exchange
Impact Knowledge exchange Assay development Development of full grant award
Start Year 2018
 
Description UCB Pharma 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution Provided constructs for IGF2-TRAP mutants.
Collaborator Contribution Expressed IGF2-TRAP proteins, perfumed formulation screens and stability studies. Re-egineered the FC linker region to avoid proteolytic degradation.
Impact None as yet
Start Year 2016
 
Title INDUCED PLURIPOTENT STEM CELLS PRODUCED FROM DENDRITIC CELLS 
Description The invention relates to induced pluripotent stem cells (iPSCs) produced from source dendritic cells (DCs). The invention also relates to synthetic DCs re-differentiated the iPSCs and which display a definitive adult phenotype rather than a primitive fetal/neonatal phenotype. The invention also relates to methods for making and methods of using the iPSCs and DCs of the invention. 
IP Reference WO2017129981 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact Establishing spin-out
 
Title INSULIN-LIKE GROWTH FACTOR 2 (IGF2) BINDING AGENTS 
Description This invention relates to mutant polypeptides comprising the IGF2 binding domain of the Insulin-like Growth Factor 2 Receptor (IGF2R) with residue P1597 is substituted for a different residue, for example H or K. Other residues which may be mutated include S1543, E1544, K1545, G1546, L1547, Q1569, S1602, G1603 and/or K1631. These IGF2 binding domains display dramatically increased binding affinity for IGF2 compared to both the wild-type and previously identified mutants and may be useful for example in cancer therapy. 
IP Reference WO2017029148 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact Development ongoing
 
Title Methods and apparatus for adding or removing material from a microfluidic arrangement 
Description The development of a method to rapidly add a fluid to many chambers in an array. 
IP Reference EP3482828 
Protection Patent application published
Year Protection Granted 2017
Licensed Yes
Impact iotaSciences Ltd is exploiting this technology
 
Title Methods and apparatus for manufacturing a microfluidic arrangement, and a microfluidic arrangement 
Description Development of a method for making an analogue of a microplate 
IP Reference GB1720771.3 
Protection Patent application published
Year Protection Granted 2017
Licensed Yes
Impact This IP is being exploited by iotaSciences LTD
 
Title Methods and apparatus for manufacturing a microfluidic arrangement, and a microfluidic arrangement' 
Description the development of methods to make microfluidic circuits involving forcing an immiscible liquid through an aqueous phase on to a substrate. 
IP Reference GB1802819.1 
Protection Patent application published
Year Protection Granted 2018
Licensed Yes
Impact This technology is being exploited by iotaSciences LTD
 
Title Universal influenza vaccine 
Description An immunogenic composition for a universal influenza vaccine. The patent application protects the composition, method of identifying the epitopes and ways of displaying the epitopes. 
IP Reference WO2018037246 
Protection Patent application published
Year Protection Granted
Licensed Yes
Impact An opinion to take out a licencing agreement has been agreed with Blue Water Vaccines. A US/UK-based startup assembled to commercialise the flu vaccine we're developing. Additional research funding in the form of a £460k research agreement has been agreed with the university due to the licencing agreement. This will pay for Dr Thompson's salary. In addition to this, a 14.5 million USD agreement regarding the development of the vaccine has been agreed. Part of this money will be spent on clinical trials in collaboration with Oxford Vaccine Group. In addition to this, Blue Water Vaccines has applied to set up an R&D facility at the BioEscalator.
 
Title Validated Assay 
Description Validated Assay for primary endpoint readout for use in clinical trials 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2017
Development Status Under active development/distribution
Impact n/a 
 
Company Name BLUE WATER VACCINES INC. 
Description A company developing a universal flu vaccine based on technology developed at the University of Oxford 
Year Established 2019 
Impact Vaccine development & clinical trials
Website https://www.bluewatervaccines.com/
 
Company Name iotaSciences Ltd 
Description This company is commercializing a novel way of performing microfluidics 
Year Established 2016 
Impact This company is commercializing a novel way of performing microfluidics
Website http://iotaSciences.com
 
Description Abingdon Science Festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A plenary presentation as part of a three day festival of science. My presentation was entitled 'Tapping the fountain of youth: Stem cells and the promise of regenerative medicine'.
Year(s) Of Engagement Activity 2017
URL http://www.atomfestival.org.uk/events/stem-cells/
 
Description All Saints Church, Marlow 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Invited to give a presentation and lead a discussion on the ethics of stem cell research.
Year(s) Of Engagement Activity 2018
 
Description Annual Rayleigh Lecture (Harrow School) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact I was invited to deliver the 2018 Rayleigh Lecture at Harrow School on the ethics of stem cell research.
Year(s) Of Engagement Activity 2018
 
Description Article 29 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact An article published in the Young Scientist Journal reviewing the lecture I gave as part of the ATOM Science Festival.
Year(s) Of Engagement Activity 2017
 
Description Article 30 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A commentary discussed the publication of one of our papers and its implications for immunotherapy.
Year(s) Of Engagement Activity 2017
 
Description CHELSEA FLOWER SHOW HIV STIGMA GARDEN 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Garden presented at RHS Chelsea 2018. Themed on HIV Stigma. Won Silver Guilt Award. Huge national and international media attention. Prime time BBC1 TV report on the garden as well as national and international TV and Radio coverage. Handed out 10,000 leaflets on site. Estimated audience greater than 3 million
Year(s) Of Engagement Activity 2018
URL https://www.medsci.ox.ac.uk/cherub-hiv-garden
 
Description Cafe Scientifique (Marlow) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact I was invited to lead a workshop for students and members of the general public on the promise of regenerative medicine.
Year(s) Of Engagement Activity 2017
 
Description Cell and Gene Therapy Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Plenary speaker at an international congress.
Year(s) Of Engagement Activity 2016
 
Description Drug Target Review 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Article on using native mass spectrometry to inform drug discovery.
Year(s) Of Engagement Activity 2017
URL https://www.drugtargetreview.com/article/23594/drug-target-review-issue-2-2017/
 
Description EIT Health Summer School Rare Cancer 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact EIT health summer in Rare cancer at two centres Budapest and Oxford.
Innovation by design and educational summer school
Year(s) Of Engagement Activity 2016
 
Description EIT health Rotterdam Meeting: Rare Cancer Project presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presenation of an EIT health project on Rare Cancer to the kick-off meeting in Rotterdam
Year(s) Of Engagement Activity 2016
 
Description European Association of Nuclear Medicine (EANM) Meeting and Congress, Vienna 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Round Table discussion at WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) Congress (Professor Katherine Vallis). This resulted in establishment of relations with Theranostics Australia, followed by formal visit of CEO and Chief Scientific Officer to Oxford to solidify and develop research overlap and potential future collaboration.
Year(s) Of Engagement Activity 2017
 
Description GlaxoSmithKline 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact An invitation to contribute to a seminar series.
Year(s) Of Engagement Activity 2016
 
Description J Larkin_Presentation about research and discussion about cancer at a local school event (Oxford, 2014) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Audience: Local members of the public, school age (between 6 and 9 years old). Presentation about being a scientist and what I do at work as well as cancer and the treatments.
Year(s) Of Engagement Activity 2014
 
Description Keynote speaker at the Faraday Institute Summer School, Cambridge 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Invited lecture on the 'Ethical challenges of stem cells and reproductive technologies'. The lecture elicited significant debate among attendees. As a result of this activity, I was invited to deliver a series of three lectrues on similar subjects across India.
Year(s) Of Engagement Activity 2019
 
Description Mercedes Family Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Manned a stall at the Mercedes family day for CRUK, explaining aspects of cancer research within the Institute. Lots of people participated and were very engaged and interested in the research being done.
Year(s) Of Engagement Activity 2017
 
Description Norway: Oslo and Bergen lectures" Challenges of Rare Cancers" and 'Evolution of an IGF2-TRAP' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Two lectures given in Bergen and video linked to Oslo Radium Hospital and Institute of Cancer Research
Year(s) Of Engagement Activity 2016
 
Description Precision Medicine and Digital Health Technology Showcase 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Poster presentation (MG): Organised by OUI to promote IP and academics where companies and investors plus other ancillary functions attend. Approach and link with Frontier IP made.
Year(s) Of Engagement Activity 2017
 
Description Production of video on our technology for measurement in critical care and respiratory medicine 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Promote our technology to potential commercial funders.
Year(s) Of Engagement Activity 2018
URL https://oxfordbrc.nihr.ac.uk/research-themes-overview/respiratory/videos-respiratory/
 
Description Publicity (press and radio) around publication of project results - Sunetra Gupta Project 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Publicity of the paper funded through the CiC grant; covered by 17 news outlets in several foreign languages. Also a radio interview on local BBC Radio Oxford
Year(s) Of Engagement Activity 2018
 
Description Scientific Advisory Board for Hungarian Academy of Sciences: Hungary Institute of Molecular Medicine 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Presentation on Oxford and Thames Valley Molecular Medicine Developments. Workshop and closed advisory board on the Development of a Hungarian Institute of Molecular Medicine.
Year(s) Of Engagement Activity 2015
 
Description Workshop on Genetic Modification (Dunottar School) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Lead a workshop and debate about the use and importance of genetic modification.
Year(s) Of Engagement Activity 2017